Nasrien Ezzeldin Ibrahim, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 59 | 2024 | 11672 | 4.600 |
Why?
|
Natriuretic Peptide, Brain | 16 | 2024 | 1723 | 3.150 |
Why?
|
Stroke Volume | 27 | 2024 | 5497 | 2.310 |
Why?
|
Diabetic Cardiomyopathies | 5 | 2024 | 90 | 1.510 |
Why?
|
Tetrazoles | 5 | 2020 | 910 | 1.390 |
Why?
|
Peptide Fragments | 12 | 2024 | 5114 | 1.310 |
Why?
|
Ventricular Dysfunction, Left | 4 | 2021 | 2119 | 1.100 |
Why?
|
Adrenergic beta-Antagonists | 4 | 2019 | 1241 | 1.000 |
Why?
|
Biphenyl Compounds | 7 | 2020 | 1007 | 0.950 |
Why?
|
Angiotensin Receptor Antagonists | 7 | 2020 | 1039 | 0.910 |
Why?
|
Fund Raising | 1 | 2024 | 49 | 0.900 |
Why?
|
Ventricular Remodeling | 4 | 2020 | 1265 | 0.870 |
Why?
|
Ventricular Function, Left | 8 | 2024 | 3878 | 0.850 |
Why?
|
Coronary Angiography | 7 | 2020 | 4472 | 0.850 |
Why?
|
Natriuretic Peptides | 3 | 2021 | 155 | 0.830 |
Why?
|
Shock, Cardiogenic | 4 | 2022 | 709 | 0.820 |
Why?
|
Cardiovascular Agents | 2 | 2020 | 840 | 0.810 |
Why?
|
Atrial Appendage | 1 | 2023 | 283 | 0.670 |
Why?
|
Baroreflex | 1 | 2020 | 149 | 0.660 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2020 | 207 | 0.650 |
Why?
|
Heart Transplantation | 5 | 2024 | 3234 | 0.620 |
Why?
|
Coronary Stenosis | 4 | 2020 | 794 | 0.600 |
Why?
|
Neprilysin | 3 | 2020 | 478 | 0.600 |
Why?
|
Endothelin-1 | 2 | 2018 | 302 | 0.590 |
Why?
|
Social Justice | 1 | 2022 | 478 | 0.570 |
Why?
|
Drug Combinations | 8 | 2020 | 2048 | 0.560 |
Why?
|
Coronary Artery Disease | 8 | 2023 | 6392 | 0.550 |
Why?
|
American Heart Association | 4 | 2024 | 1045 | 0.540 |
Why?
|
Healthcare Disparities | 6 | 2024 | 3357 | 0.540 |
Why?
|
Heart Rate | 2 | 2019 | 4197 | 0.530 |
Why?
|
Angiography | 3 | 2018 | 1599 | 0.530 |
Why?
|
Cardiology | 7 | 2024 | 1667 | 0.520 |
Why?
|
Renin-Angiotensin System | 2 | 2018 | 737 | 0.510 |
Why?
|
Catheterization | 2 | 2018 | 1432 | 0.510 |
Why?
|
Atrial Natriuretic Factor | 3 | 2021 | 350 | 0.510 |
Why?
|
Catheters | 1 | 2018 | 426 | 0.510 |
Why?
|
Risk Assessment | 12 | 2020 | 23981 | 0.490 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 170 | 0.470 |
Why?
|
Proteomics | 4 | 2020 | 3843 | 0.440 |
Why?
|
Dyspnea | 2 | 2021 | 1344 | 0.430 |
Why?
|
Defibrillators, Implantable | 2 | 2022 | 1490 | 0.420 |
Why?
|
Humans | 91 | 2024 | 761326 | 0.420 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.410 |
Why?
|
Exercise Tolerance | 4 | 2024 | 836 | 0.400 |
Why?
|
Cardiovascular Diseases | 10 | 2024 | 15499 | 0.390 |
Why?
|
Disease Management | 2 | 2021 | 2504 | 0.370 |
Why?
|
Heart Neoplasms | 1 | 2014 | 362 | 0.370 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2017 | 555 | 0.360 |
Why?
|
Acute Kidney Injury | 3 | 2020 | 1926 | 0.360 |
Why?
|
Renal Insufficiency | 1 | 2016 | 809 | 0.360 |
Why?
|
Prognosis | 14 | 2024 | 29588 | 0.350 |
Why?
|
Pericardium | 1 | 2014 | 675 | 0.340 |
Why?
|
Health Status Disparities | 2 | 2024 | 1852 | 0.340 |
Why?
|
Peripheral Arterial Disease | 2 | 2018 | 1272 | 0.340 |
Why?
|
Predictive Value of Tests | 10 | 2024 | 15262 | 0.320 |
Why?
|
Salaries and Fringe Benefits | 2 | 2021 | 257 | 0.310 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2024 | 12144 | 0.300 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 7999 | 0.290 |
Why?
|
Heart-Assist Devices | 4 | 2022 | 1287 | 0.280 |
Why?
|
Aldehyde Reductase | 2 | 2024 | 71 | 0.280 |
Why?
|
Guideline Adherence | 1 | 2017 | 2221 | 0.280 |
Why?
|
Prospective Studies | 16 | 2021 | 54405 | 0.270 |
Why?
|
Diuretics | 3 | 2020 | 610 | 0.270 |
Why?
|
Troponin | 2 | 2021 | 501 | 0.270 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2019 | 1517 | 0.270 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4432 | 0.270 |
Why?
|
Troponin I | 3 | 2020 | 651 | 0.260 |
Why?
|
Middle Aged | 30 | 2024 | 220774 | 0.260 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3687 | 0.260 |
Why?
|
Aged | 27 | 2024 | 169179 | 0.260 |
Why?
|
Contrast Media | 1 | 2019 | 5310 | 0.250 |
Why?
|
Male | 38 | 2024 | 360621 | 0.250 |
Why?
|
Female | 40 | 2024 | 392485 | 0.250 |
Why?
|
Atrial Fibrillation | 1 | 2023 | 5127 | 0.240 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2241 | 0.240 |
Why?
|
Artificial Intelligence | 1 | 2019 | 2578 | 0.230 |
Why?
|
ROC Curve | 4 | 2021 | 3572 | 0.220 |
Why?
|
Electrocardiography | 1 | 2017 | 6382 | 0.220 |
Why?
|
Registries | 5 | 2023 | 8223 | 0.220 |
Why?
|
Echocardiography | 4 | 2024 | 4991 | 0.220 |
Why?
|
Time Factors | 9 | 2023 | 39974 | 0.210 |
Why?
|
United States | 17 | 2024 | 72317 | 0.200 |
Why?
|
Treatment Outcome | 11 | 2024 | 64645 | 0.200 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5439 | 0.190 |
Why?
|
Asymptomatic Diseases | 1 | 2024 | 587 | 0.190 |
Why?
|
Myocardial Infarction | 5 | 2022 | 11454 | 0.180 |
Why?
|
Research Design | 1 | 2016 | 6178 | 0.180 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 857 | 0.170 |
Why?
|
Endorphins | 1 | 2020 | 74 | 0.170 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 75 | 0.170 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2024 | 515 | 0.170 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39108 | 0.170 |
Why?
|
Exercise Test | 2 | 2024 | 2129 | 0.170 |
Why?
|
Pharmacological Phenomena | 1 | 2019 | 11 | 0.170 |
Why?
|
Hyperlipoproteinemias | 1 | 2019 | 20 | 0.160 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 1703 | 0.160 |
Why?
|
Glomerular Filtration Rate | 2 | 2018 | 2176 | 0.160 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2020 | 325 | 0.160 |
Why?
|
Recovery of Function | 2 | 2020 | 2977 | 0.150 |
Why?
|
Risk Factors | 11 | 2020 | 74152 | 0.150 |
Why?
|
Hospital Mortality | 4 | 2024 | 5291 | 0.150 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 539 | 0.140 |
Why?
|
Apolipoproteins | 1 | 2019 | 326 | 0.140 |
Why?
|
Adenocarcinoma | 1 | 2014 | 6332 | 0.140 |
Why?
|
Health Promotion | 2 | 2019 | 2213 | 0.140 |
Why?
|
Cardiovascular System | 1 | 2024 | 835 | 0.130 |
Why?
|
Angiotensins | 1 | 2017 | 143 | 0.130 |
Why?
|
Evaluation Studies as Topic | 1 | 2018 | 1626 | 0.130 |
Why?
|
Reimbursement Mechanisms | 1 | 2021 | 665 | 0.130 |
Why?
|
Glucosides | 1 | 2020 | 512 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2022 | 1317 | 0.130 |
Why?
|
Consensus | 5 | 2024 | 3122 | 0.130 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2017 | 361 | 0.120 |
Why?
|
Autonomic Nervous System | 1 | 2020 | 701 | 0.120 |
Why?
|
Chest Pain | 1 | 2022 | 1090 | 0.120 |
Why?
|
Incidence | 5 | 2023 | 21336 | 0.120 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 152 | 0.120 |
Why?
|
Dyslipidemias | 1 | 2022 | 868 | 0.120 |
Why?
|
Cachexia | 1 | 2016 | 199 | 0.120 |
Why?
|
Catheterization, Peripheral | 1 | 2018 | 342 | 0.120 |
Why?
|
Patient Care Management | 1 | 2017 | 302 | 0.120 |
Why?
|
Kidney Function Tests | 1 | 2016 | 678 | 0.110 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 916 | 0.110 |
Why?
|
Disease Progression | 4 | 2018 | 13500 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 590 | 0.110 |
Why?
|
Physicians, Women | 1 | 2019 | 508 | 0.110 |
Why?
|
Sex Factors | 4 | 2021 | 10551 | 0.110 |
Why?
|
Myocarditis | 1 | 2021 | 786 | 0.110 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 7389 | 0.110 |
Why?
|
Prevalence | 5 | 2024 | 15719 | 0.110 |
Why?
|
Tissue Donors | 2 | 2021 | 2331 | 0.110 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15835 | 0.110 |
Why?
|
Chronic Disease | 3 | 2017 | 9319 | 0.110 |
Why?
|
Creatinine | 1 | 2019 | 1899 | 0.110 |
Why?
|
Hospitalization | 3 | 2024 | 10715 | 0.110 |
Why?
|
Blood Proteins | 1 | 2018 | 1180 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2019 | 961 | 0.100 |
Why?
|
Cardiomyopathies | 1 | 2024 | 1964 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2017 | 727 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2110 | 0.100 |
Why?
|
Retrospective Studies | 7 | 2024 | 80575 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1443 | 0.100 |
Why?
|
Analysis of Variance | 2 | 2019 | 6231 | 0.100 |
Why?
|
Hepatitis C, Chronic | 1 | 2019 | 1032 | 0.090 |
Why?
|
Health Status | 2 | 2020 | 4075 | 0.090 |
Why?
|
Adult | 9 | 2024 | 221122 | 0.090 |
Why?
|
Stroke | 2 | 2022 | 9749 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2014 | 13333 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2024 | 10764 | 0.090 |
Why?
|
Quality of Life | 2 | 2022 | 13355 | 0.080 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12450 | 0.080 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 1461 | 0.080 |
Why?
|
Heart | 2 | 2019 | 4405 | 0.080 |
Why?
|
Patient Selection | 2 | 2022 | 4244 | 0.080 |
Why?
|
Cause of Death | 1 | 2019 | 3685 | 0.080 |
Why?
|
Quality Improvement | 1 | 2023 | 3800 | 0.080 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 26108 | 0.080 |
Why?
|
Outpatients | 1 | 2016 | 1596 | 0.080 |
Why?
|
Massachusetts | 2 | 2018 | 8837 | 0.070 |
Why?
|
Survival Analysis | 2 | 2019 | 10075 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10203 | 0.070 |
Why?
|
Cohort Studies | 4 | 2019 | 41440 | 0.070 |
Why?
|
Oxidative Stress | 1 | 2018 | 3108 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2019 | 3057 | 0.070 |
Why?
|
Medicare | 2 | 2021 | 6758 | 0.070 |
Why?
|
Double-Blind Method | 3 | 2024 | 12329 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2019 | 58946 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3796 | 0.060 |
Why?
|
Ambulatory Care | 1 | 2016 | 2775 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3630 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14597 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8635 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5841 | 0.060 |
Why?
|
Apoptosis | 1 | 2018 | 9474 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8539 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20092 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4812 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 201 | 0.050 |
Why?
|
Telemedicine | 1 | 2018 | 3041 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2022 | 5247 | 0.040 |
Why?
|
Habits | 1 | 2021 | 147 | 0.040 |
Why?
|
Telephone | 1 | 2022 | 627 | 0.040 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2024 | 850 | 0.040 |
Why?
|
Kidney Tubules | 1 | 2020 | 449 | 0.040 |
Why?
|
Databases, Factual | 2 | 2024 | 7954 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2024 | 1863 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 338 | 0.040 |
Why?
|
Quinoxalines | 1 | 2019 | 296 | 0.040 |
Why?
|
Delivery, Obstetric | 1 | 2024 | 940 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2020 | 943 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2024 | 1535 | 0.040 |
Why?
|
Pilot Projects | 2 | 2021 | 8632 | 0.030 |
Why?
|
Animals | 4 | 2022 | 168388 | 0.030 |
Why?
|
Morbidity | 1 | 2022 | 1750 | 0.030 |
Why?
|
Advisory Committees | 1 | 2021 | 785 | 0.030 |
Why?
|
Podocytes | 1 | 2020 | 406 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2022 | 1728 | 0.030 |
Why?
|
Th17 Cells | 1 | 2021 | 793 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3420 | 0.030 |
Why?
|
Waiting Lists | 1 | 2019 | 765 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2281 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2019 | 675 | 0.030 |
Why?
|
Adiponectin | 1 | 2020 | 1113 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2019 | 858 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2024 | 2920 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2019 | 2927 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2024 | 3710 | 0.030 |
Why?
|
Standard of Care | 1 | 2016 | 550 | 0.030 |
Why?
|
Societies, Medical | 1 | 2024 | 3905 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 6210 | 0.030 |
Why?
|
Hepacivirus | 1 | 2019 | 1337 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2193 | 0.020 |
Why?
|
Primary Prevention | 1 | 2019 | 1186 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6086 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2016 | 879 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18234 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2016 | 908 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1976 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2248 | 0.020 |
Why?
|
Hemodynamics | 1 | 2019 | 4167 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3824 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9639 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9534 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3531 | 0.020 |
Why?
|
Critical Illness | 1 | 2020 | 2722 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3744 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2817 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12972 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2021 | 14409 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 59196 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7238 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14665 | 0.020 |
Why?
|
Boston | 1 | 2018 | 9333 | 0.020 |
Why?
|
Weight Loss | 1 | 2016 | 2683 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2018 | 3597 | 0.020 |
Why?
|
Models, Biological | 1 | 2020 | 9468 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10191 | 0.010 |
Why?
|
Mice | 2 | 2021 | 81474 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9180 | 0.010 |
Why?
|
Survival Rate | 1 | 2017 | 12710 | 0.010 |
Why?
|
Pregnancy | 1 | 2024 | 29858 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7872 | 0.010 |
Why?
|
Obesity | 1 | 2022 | 12934 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 12949 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2020 | 15647 | 0.010 |
Why?
|